Bicocca Open Archive

Logo unimib boa
FALANGA, ANNA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 8.368
AS - Asia 4.649
EU - Europa 3.500
SA - Sud America 972
AF - Africa 94
OC - Oceania 7
Continente sconosciuto - Info sul continente non disponibili 2
Totale 17.592
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 8.125
SG - Singapore 2.075
HK - Hong Kong 1.330
RU - Federazione Russa 994
BR - Brasile 794
CN - Cina 657
IE - Irlanda 562
SE - Svezia 526
IT - Italia 504
DE - Germania 442
VN - Vietnam 289
CA - Canada 171
GB - Regno Unito 111
AT - Austria 84
AR - Argentina 72
UA - Ucraina 72
ID - Indonesia 61
MX - Messico 55
IN - India 52
BD - Bangladesh 45
FR - Francia 35
NL - Olanda 35
ZA - Sudafrica 35
EC - Ecuador 30
FI - Finlandia 27
JP - Giappone 25
ES - Italia 23
PL - Polonia 23
IQ - Iraq 19
MA - Marocco 18
CO - Colombia 16
RO - Romania 16
CL - Cile 15
TR - Turchia 15
DK - Danimarca 12
KR - Corea 12
PE - Perù 12
PY - Paraguay 12
TN - Tunisia 10
VE - Venezuela 10
SA - Arabia Saudita 9
CH - Svizzera 8
UY - Uruguay 7
UZ - Uzbekistan 7
AE - Emirati Arabi Uniti 6
IL - Israele 6
MU - Mauritius 6
AU - Australia 5
EG - Egitto 5
ET - Etiopia 5
KZ - Kazakistan 5
DO - Repubblica Dominicana 4
GR - Grecia 4
JO - Giordania 4
OM - Oman 4
PK - Pakistan 4
BO - Bolivia 3
CR - Costa Rica 3
IR - Iran 3
KE - Kenya 3
MY - Malesia 3
NP - Nepal 3
PA - Panama 3
PH - Filippine 3
PT - Portogallo 3
AL - Albania 2
BA - Bosnia-Erzegovina 2
BG - Bulgaria 2
BY - Bielorussia 2
CZ - Repubblica Ceca 2
DZ - Algeria 2
GA - Gabon 2
GE - Georgia 2
HN - Honduras 2
JM - Giamaica 2
KH - Cambogia 2
LT - Lituania 2
NE - Niger 2
NZ - Nuova Zelanda 2
RS - Serbia 2
SN - Senegal 2
TH - Thailandia 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AM - Armenia 1
AO - Angola 1
AZ - Azerbaigian 1
BE - Belgio 1
BH - Bahrain 1
BW - Botswana 1
CI - Costa d'Avorio 1
EE - Estonia 1
GN - Guinea 1
GT - Guatemala 1
KG - Kirghizistan 1
LB - Libano 1
LK - Sri Lanka 1
LV - Lettonia 1
NO - Norvegia 1
SK - Slovacchia (Repubblica Slovacca) 1
SR - Suriname 1
Totale 17.589
Salva come PNG Salva come JPEG
Città #
Hong Kong 1.325
Singapore 1.068
Ann Arbor 980
Fairfield 840
Ashburn 585
Dublin 558
Woodbridge 412
Wilmington 372
Chandler 368
Houston 360
New York 320
Frankfurt am Main 308
Princeton 308
Dallas 305
Cambridge 281
Seattle 261
Santa Clara 199
Beijing 155
Altamura 140
Lawrence 140
Jacksonville 139
Los Angeles 115
Milan 109
Chicago 104
Ho Chi Minh City 95
The Dalles 93
Moscow 85
Ottawa 80
San Diego 80
São Paulo 75
Hanoi 63
Nuremberg 50
Toronto 50
Buffalo 48
Vienna 47
Andover 46
Jakarta 39
Council Bluffs 37
Falls Church 32
Hefei 31
Shanghai 31
London 28
Salt Lake City 28
Rio de Janeiro 26
Redmond 24
Nanjing 23
Dearborn 22
Guangzhou 22
Tokyo 21
Dong Ket 20
Brasília 19
Warsaw 18
Norwalk 17
Orem 17
Phoenix 17
Brooklyn 15
Florence 15
Tampa 15
Helsinki 14
Atlanta 13
Elk Grove Village 13
Montreal 13
Poplar 13
Campinas 12
Columbus 12
Belo Horizonte 11
Chengdu 11
Curitiba 11
Denver 11
Dhaka 11
Jinan 11
Johannesburg 11
Rome 11
Seoul 11
Wuhan 11
Ankara 10
Boardman 10
Fuzhou 10
Hangzhou 10
Lancaster 10
Porto Alegre 10
Quito 10
Charlotte 9
Fara Gera d'Adda 9
Guayaquil 9
Mexico City 9
Sterling 9
Amsterdam 8
Cape Town 8
Guarulhos 8
Lima 8
Querétaro 8
Salvador 8
Sorocaba 8
Baghdad 7
Boston 7
Changsha 7
Haiphong 7
Hải Dương 7
Lappeenranta 7
Totale 11.494
Salva come PNG Salva come JPEG
Nome #
A microphysiological early metastatic niche on a chip reveals how heterotypic cell interactions and inhibition of integrin subunit β3 impact breast cancer cell extravasation 286
D-dimer testing, with gender-specific cutoff levels, is of value to assess the individual risk of venous thromboembolic recurrence in non-elderly patients of both genders: a post hoc analysis of the DULCIS study 267
Treatment of venous thromboembolism with tinzaparin in oncological patients 249
Fibrinolytic Proteins and Factor XIII as Predictors of Thrombotic and Hemorrhagic Complications in Hospitalized COVID-19 Patients 233
FANCM c.5791C>T nonsense mutation (rs144567652) induces exon skipping, affects DNA repair activity and is a familial breast cancer risk factor 232
Long-term outcomes of patients with cerebral vein thrombosis: a multicenter study 219
Management of bleeding in acquired hemophilia A: results from the European Acquired Haemophilia (EACH2) Registry 214
Thrombotic biomarkers for risk prediction of malignant disease recurrence in patients with early stage breast cancer 214
Prevention of venous thromboembolism in patients with cancer: Guidelines of the Italian Society for Haemostasis and Thrombosis (SISET) 214
Tissue Plasminogen Activator Levels and Risk of Breast Cancer in a Case-Cohort Study on Italian Women: Results from the Moli-sani Study 204
Demographic and clinical data in acquired hemophilia A: results from the European Acquired Haemophilia Registry (EACH2) 196
Trial of Rivaroxaban in AntiPhospholipid Syndrome (TRAPS): Two-year outcomes after the study closure 179
Post-operative heparin reduces early venous thrombotic complications after orthotopic paediatric liver transplantation 176
The use of direct oral anticoagulants for primary thromboprophylaxis in ambulatory cancer patients: Guidance from the SSC of the ISTH 175
Thrombocytopenia and Mortality Risk in Patients With Atrial Fibrillation: An Analysis From the START Registry 173
ISTH interim guidance on recognition and management of coagulopathy in COVID-19 168
Activated prothrombin complex concentrate (FEIBA ® ) in acquired haemophilia A: a large multicentre Italian study – the FAIR Registry 167
Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Clinical Practice Guideline Update Summary 162
Clozapine-induced anemia: A case-report 162
Venous thromboembolism and cancer: Guidelines of the Italian Association of Medical Oncology (AIOM) 160
Proceedings of the Second “International Conference on Thrombosis and Hemostasis Issues in Cancer”. September 19-21, 2003. Bergamo, Italy 160
Hemostatic biomarkers in occult cancer and cancer risk prediction 158
Anticoagulation in thrombocytopenic patients with hematological malignancy: A multinational clinical vignette-based experiment 151
DOACs and “newer” hemophilia therapies in COVID-19: Reply 150
Cancer associated thrombosis in everyday practice: perspectives from GARFIELD-VTE 147
Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Clinical Practice Guideline Update 146
Fundamental Research in Oncology and Thrombosis 2 (FRONTLINE 2): A Follow-Up Survey 144
Laboratory haemostasis monitoring in COVID-19 144
Grey zones on the use of new oral anticoagulants in atrial fibrillation. Expert opinion [Grey zones sull'uso dei nuovi anticoagulanti orali nella fibrillazione atriale. Opinioni degli esperti] 144
Addressing and proposing solutions for unmet clinical needs in the management of myeloproliferative neoplasm-associated thrombosis: A consensus-based position paper 142
Thrombin generation predicts early recurrence in breast cancer patients 142
Incidence of thrombotic complications in patients with haematological malignancies with central venous catheters: A prospective multicentre study 140
D-dimer to guide the duration of anticoagulation in patients with venous thromboembolism: a management study 139
Pharmacological Agents Targeting Thromboinflammation in COVID-19: Review and Implications for Future Research 138
COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up: JACC State-of-the-Art Review 137
Polymorphonuclear leukocyte activation and hemostasis in patients with essential thrombocythemia and polycythemia vera 136
Platelet cut-off for anticoagulant therapy in thrombocytopenic patients with blood cancer and venous thromboembolism: an expert consensus 132
Managing Anti-Platelet Therapy in Thrombocytopaenic Patients with Haematological Malignancy: A Multinational Clinical Vignette-Based Experiment 132
Pathogenesis and management of the bleeding diathesis in acute promyelocytic leukaemia 131
Combined use of antifibrinolytics and activated prothrombin complex concentrate (aPCC) is not related to thromboembolic events in patients with acquired haemophilia A: data from FAIR Registry 131
Anticoagulation resumption after intracranial hemorrhage in patients treated with VKA and DOACs 130
Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update 2014 128
Preliminary study to identify cancer patients at high risk of venous thrombosis following major surgery 128
Guidance for the Management of Patients with Vascular Disease or Cardiovascular Risk Factors and COVID-19: Position Paper from VAS-European Independent Foundation in Angiology/Vascular Medicine 128
Vitamin K-Dependent Procoagulant in Cancer Cells: A Potential Target for the Antimetastatic Effect of Warfarin? 126
Unbalanced plasma control of TxA2 and PGI2 synthesis in Vitamin E deficient rats 126
Prospective Assessment of Clinical Risk Factors and Biomarkers of Hypercoagulability for the Identification of Patients with Lung Adenocarcinoma at Risk for Cancer-Associated Thrombosis: The Observational ROADMAP-CAT Study 126
Low levels of ADAMTS-13 with high anti-ADAMTS-13 antibodies during remission of immune-mediated thrombotic thrombocytopenic purpura highly predict for disease relapse: A multi-institutional study 126
THE HYPERCOAGULABLE STATE IN CANCER-PATIENTS - EVIDENCE FOR IMPAIRED THROMBIN INHIBITIONS 125
RECOMBINANT VERSUS HIGH-SENSITIVITY CONVENTIONAL THROMBOPLASTIN - A RANDOMIZED CLINICAL-STUDY IN PATIENTS ON ORAL ANTICOAGULATION 123
Procoagulant activity of mouse transformed cells: Different expression in freshly isolated or cultured cells 123
Thrombophilic status may predict prognosis in patients with metastatic BRAFV600-mutated melanoma who are receiving BRAF inhibitors 122
The impact of all-trans-retinoic acid on the coagulopathy of acute promyelocytic leukemia 122
Venous thromboembolism prophylaxis and treatment in patients with cancer: american society of clinical oncology clinical practice guideline update 120
Procoagulant mechanisms in tumour cells 120
A Multidisciplinary Approach on the Perioperative Antithrombotic Management of Patients With Coronary Stents Undergoing Surgery: Surgery After Stenting 2 120
V. Plasmaferesi terapeutica 120
Molecular biomarkers of thrombosis in myeloproliferative neoplasms 119
Pathophysiology 1. Mechanisms of Thrombosis in Cancer Patients 118
Molecular basis for the relationship between thrombosis and cancer 117
The Italian START-Register on anticoagulation with focus on atrial fibrillation 116
Association of plasma Protein C and CCL18 levels with neurodegenerative measures in Multiple Sclerosis patients 116
The mechanisms of cancer-associated thrombosis 115
Phase III studies on novel oral anticoagulants for stroke prevention in atrial fibrillation: a look beyond the excellent results 115
Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome 115
The effect of very-low-dose warfarin on markers of hypercoagulation in metastatic breast cancer: Results from a randomized trial 113
Antithrombotic medication in cancer-associated thrombocytopenia: Current evidence and knowledge gaps 113
Practical management of ibrutinib in the real life: Focus on atrial fibrillation and bleeding 113
The prevention and management of asparaginase-related venous thromboembolism in adults: Guidance from the SSC on Hemostasis and Malignancy of the ISTH 113
Evaluation of nucleated red blood cell count by Sysmex XE-2100 in patients with thalassaemia or sickle cell anaemia and in neonates 112
Thrombosis in myeloproliferative disorders: pathogenetic facts and speculation 111
Pathogenesis and treatment of thrombohemorrhagic diathesis in acute promyelocytic leukemia 110
INEFFICACY OF INTRAVENOUS IMMUNOGLOBULIN IN PATIENTS WITH LOW-RISK THROMBOTIC THROMBOCYTOPENIC PURPURA/HEMOLYTIC-UREMIC SYNDROME 110
Tissue Factor Expression on Platelet Surface during Preparation and Storage of Platelet Concentrates 110
Management of Cancer-associated Disseminated Intravascular Coagulation: guidance from the SSC of the ISTH 109
Eradication of acquired hemophilia associated with indolent non-Hodgkin lymphoma by a disease specific treatment 109
La coagulopatia indotta da trauma 109
Supranormal antithrombin III levels induced by concentrate administration are ineffective in quenching thrombin generation in acute promyelocytic leukemia 109
Hemostatic biomarkers in cancer progression 108
Recurrent venous thromboembolism in anticoagulated patients with cancer: management and short-term prognosis 107
Comparison between different D-Dimer cutoff values to assess the individual risk of recurrent venous thromboembolism: Analysis of results obtained in the DULCIS study 107
External validation of the DASH prediction rule: a retrospective cohort study 107
Risk of Venous Thromboembolism in Surgical Elderly Patients. 106
The predictive ability of bleeding risk stratification models in very old patients on vitamin K antagonist treatment for venous thromboembolism: Results of the prospective collaborative EPICA study 106
Cancer and venous thromboembolism 106
Microparticles in tumor progression 105
Anticoagulation in Italian patients with venous thromboembolism and thrombophilic alterations: findings from START2 register study 105
Phospholipid-dependent procoagulant activity is highly expressed by circulating microparticles in patients with Essential Thrombocythemia 104
Venous thromboembolism in the hematologic malignancies 103
Type and dose of heparin in Covid-19: Reply 103
Proceedings of the Fifth International Conference on Thrombosis and Hemostasis Issues in Cancer, held in Stresa - Italy, April 23-25, 2010. Preface. 103
Pharmacological inhibition of thromboxane-synthetase and platelet aggregation: Modulatory role of cyclooxygenase products. 101
The effect of Vitamin E or selenium on the oxidant-antioxidant balance in rats 101
International longitudinal registry of patients with atrial fibrillation and treated with rivaroxaban: RIVaroxaban Evaluation in Real life setting (RIVER) 100
Meeting Report EuroG20 Meeting on Cancer-Associated Thrombosis (CAT) Bergamo, Italy 7 April 2016 100
Hypercoagulation screening as an innovative tool for risk assessment, early diagnosis and prognosis in cancer: The HYPERCAN study 100
Thrombosis in myeloproliferative neoplasms 99
Soluble stroma-related biomarkers of pancreatic cancer 99
The International Conference on Thrombosis and Hemostasis Issues in Cancer (ICTHIC) at the Peak of Adolescence - 15 Years and Counting 99
Acute Promyelocytic Leukemia Coagulopathy 99
Totale 13.647
Salva come PNG Salva come JPEG
Categoria #
all - tutte 79.181
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 79.181
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20211.449 0 0 0 0 0 214 287 296 173 162 187 130
2021/20221.551 160 169 178 92 61 74 93 102 68 97 110 347
2022/20232.055 369 575 190 140 96 407 7 91 97 17 41 25
2023/20241.482 27 52 20 18 227 407 262 46 245 20 5 153
2024/20254.342 306 732 200 167 356 74 291 96 417 613 332 758
2025/20264.356 656 607 830 950 927 386 0 0 0 0 0 0
Totale 18.271